Active	Status	Sponsor type	Region	Phase	Filter
1 Active 2 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
lademirsen (RG-012) / Regulus Therapeutics
2019-004394-10: Study of lademirsen (SAR339375) in patients with Alport Syndrome	Not yet recruiting	2	45	Europe	Lademirsen, SAR339375, Solution for injection	Genzyme Corporation, Genyme Corporation	Congenital, hereditary and neonatal diseases, Alport's Syndrome, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]